Mayne Pharma Group Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Aaron Gray
- Full Time Employees
- 450
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1538 Main North Road Salisbury South SA Australia 5106
- IPO Date
- Mar 22, 2013
- Website
- maynepharma.com
- Similar Companies
- Business
- Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on the commercialization and manufacture of branded and generic pharmaceutical products primarily in the women’s health, dermatology, and international markets. The company's product portfolio includes oral drug delivery systems and contract development and manufacturing services, with key therapeutic areas such as women's health and dermatology. Mayne Pharma markets products under leading brands including NEXTSTELLIS, ANNOVERA, IMVEXXY, BIJUVA, RHOFADE, WYNZORA, SOOLANTRA, and gACCUTANE, and also offers authorized generic versions such as AG ORACEA. The company operates in Australia, New Zealand, the United States, Canada, Europe, and Asia, and maintains FDA-approved manufacturing facilities in South Australia and North Carolina, USA. Founded in 2005 and headquartered in Salisbury South, Australia, Mayne Pharma serves global pharmaceutical markets with a strong commercial and operational presence. Recent major company developments include the acquisition of the global rights to RHOFADE cream from Novan, Inc. and EPI Health, LLC, enhancing its dermatology portfolio. The company has launched multiple new products in fiscal 2024 such as RHOFADE, WYNZORA, SOOLANTRA, and gACCUTANE, contributing to significant revenue growth. Mayne Pharma has achieved a breakeven run rate for its key women's health product NEXTSTELLIS and expanded manufacturing capabilities with a new encapsulator enabling the launch of KAPANOL 200mg. The company has also experienced growth in demand for opioid products KADIAN and KAPANOL in Canada and Europe. In early 2025, Mayne Pharma entered into an agreement for acquisition by U.S.-based Cosette Pharmaceuticals for approximately USD 430 million, a transaction that would consolidate Mayne Pharma's portfolio into a larger global women’s health and dermatology specialty pharma platform. Mayne Pharma is listed on the Australian Securities Exchange and is recognized for its specialty pharmaceuticals expertise across women’s health and dermatology, complemented by contract manufacturing services. The company employs over 450 personnel globally and continues to focus on product innovation, portfolio expansion, and operational efficiency in its ongoing growth strategy. Its strategic partnership and acquisition by Cosette Pharmaceuticals in 2025 underscore its position and future potential within the global specialty pharmaceutical industry.
Contrasting Otsuka (OTCMKTS:OTSKY) and Mayne Pharma Group (OTCMKTS:MAYNF)
Mayne Pharma Group Limited (MAYNF) Discusses U.S. Launch and Business Model of DistributeRx Transcript
Mayne Pharma Group Limited (MAYNF) Q2 2026 Earnings Call Transcript
Mayne Pharma Group (OTCMKTS:MAYNF) Stock Price Up 1.4% – Should You Buy?
Mayne Pharma Group Limited (MAYNF) Shareholder/Analyst Call Transcript
Mayne Pharma Group (OTCMKTS:MAYNF) Shares Down 9.7% – Here’s What Happened
Termination of Proposed Acquisition of Mayne Pharma
Australia Blocks U.S.-Based Cosette's $387.2 Million Takeover of Mayne Pharma
Australia blocks Cosette Pharmaceuticals bid to buy Mayne Pharma
Australia's Mayne Pharma falls as treasurer considers blocking Cosette's $437 million bid
Cosette's attempt to drop $438 million Mayne Pharma deal denied by court
Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal
Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women's Health and Dermatology
FEDERAL CONTRACEPTION PROPOSAL TO EXPAND ACCESS AND AFFORDABLE COVERAGE PAVES A STRONGER PATH FOR MAYNE PHARMA'S GROWTH IN WOMEN'S HEALTH
Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement
Mayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call Transcript